Orexin Receptor (OX Receptor)

Orexin Receptor (OX Receptor) Related Products (29):

By Effects:	Inhibitor (1) Agonists (9) Antagonists (10) Activators (5) Modulator (1)

Cat. No.	Product Name	Effect	Purity

HY-133898

Danavorexton	Activator	98.36%
Danavorexton (TAK-925) is an orexin receptor agonist with brain permeability. Danavorexton induces a physiological pattern of OX2R activation in vitro to wake up sleepy mice and improve sleepiness symptoms.

HY-P1339A

Orexin B, human TFA	Agonist	99.16%
Orexin B, human (TFA) is an endogenous agonist at Orexin receptor with K_is of 420 and 36 nM for OX1 and OX2, respectively.

HY-15653

Filorexant	Antagonist	99.27%
Filorexant (MK-6096) is an orally bioavailable potent and selective reversible antagonist of OX1 and OX2 receptor(<3 nM in binding).

HY-P99945

Revdofilimab	Activator	99.35%
Revdofilimab (ABBV-368) is a human IgG1 agonist monoclonal antibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory T cell subsets and T regulatory cells.

HY-P99836

Cudarolimab	Inhibitor
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research.

HY-168571

BTF
BTF shows a selective binding affinity for OX1R with the K_i values of 2.33 nM and 62.8 nM of OX1R and OX2R, respectively.

HY-159835

Oveporexton	Agonist
Oveporexton is an orexin type 2 receptor (OX2R) agonist.

HY-137452A

(R,R)-Suntinorexton	Agonist	99.13%
(R,R)-Suntinorexton is a isomeride of Suntinorexton (HY-137452). Suntinorexton is a orexin type 2 receptor agonist.

HY-10806

SB-649868	Antagonist	99.87%
SB-649868 is a potent and selective orally active orexin (OX) 1 and OX₂ receptor antagonist (pK_i =9.4 and 9.5 at the OX₁ and OX₂ receptor, respectively).

HY-136181A

YNT-185	Agonist	98.36%
YNT-185 is a nonpeptide, selective orexin type-2 receptor (OX2R) agonist, with EC₅₀s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 ameliorates narcolepsy-cataplexy symptoms in mouse models.

HY-147294

Nivasorexant	Antagonist	99.74%
Nivasorexant is a potent orexin receptor antagonist.

HY-137440A

Firazorexton hydrate		99.94%
Firazorexton hydrate (TAK-994) is a potent, brain-penetrant, and orally active orexin type 2 receptor (OX2R) agonist (EC₅₀: 19 nM). Firazorexton hydrate inhibits fragmentation of wakefulness and cataplexy-like episodes in mouse models of narcolepsy.

HY-12301

MK-3697	Antagonist	98.83%
MK-3697 is an isonicotinamide small molecule, acting as a potent and selective Orexin 2 receptor antagonist with Ki = 0.

HY-P1349

Orexin B, rat, mouse	Agonist
Orexin B, rat, mouse (Rat orexin B) is an endogenous agonist at Orexin receptor with K_is of 420 and 36 nM for OX1 and OX2, respectively.

HY-P1349A

Orexin B, rat, mouse TFA	Agonist
Orexin B, rat, mouse (Rat orexin B) TFA is an endogenous orexin receptor agonist. Orexin B, rat, mouse TFA binds and activates two closely related orphan G protein-coupled receptors OX1-R and OX2-R. Orexin B, rat, mouse TFA stimulates food intake and energy expenditure and plays a significant role in sleep-wakefulness regulation.

HY-152843

Fazamorexant	Antagonist	99.73%
Fazamorexant (YZJ-1139) is a potent orexin receptor antagonist. Fazamorexant can be used for insomnia research.

HY-136922

Orexin receptor antagonist 2	Antagonist	98.04%
Orexin receptor antagonist 2 (compound 30) is a potent orexin receptor antagonist with pK_is of 7.69 and 9.78. Orexin receptor antagonist 2 has the potential for the research of insomnia.

HY-P99911

Efizonerimod alfa	Activator	98.57%
Efizonerimod alfa is a potent monoclonal antibody OX40 activator. Efizonerimod alfa can be used for cancer research.

HY-137093

Orexin receptor antagonist 3	Antagonist	99.62%
Orexin receptor antagonist 3 (example 216) is an orexin receptor antagonist, which is extracted from the patent WO2011050198A1.

HY-13796

IPSU	Antagonist	98.10%
IPSU is a selective, orally available and brain penetrant OX2R antagonist with a pK_i of 7.85.

Name
Email *

	Sorry, but the email address you supplied was invalid.